T1	intervention-participants 390 393	251
T2	control-participants 501 503	50
T3	control 484 497	control group
T4	intervention 0 55	Elevated plasma tissue inhibitor of metalloproteinase-1
T5	outcome 1393 1417	TTP and overall survival
T6	outcome 1203 1228	time to progression (TTP)
T7	iv-cont-median 1230 1237	84 days
T8	cv-cont-median 1241 1249	174 days
T9	outcome 1266 1282	overall survival
T10	iv-cont-median 1284 1292	141 days
T11	cv-cont-median 1296 1304	860 days
T12	outcome 1148 1169	clinical benefit rate
T13	iv-bin-percent 1177 1180	16%
T14	cv-bin-percent 1184 1187	42%
T15	outcome 927 940	Plasma TIMP-1
T17	cv-bin-abs 1029 1031	19
T18	cv-bin-percent 1042 1046	7.6%
T16	iv-cont-mean 1015 1024	373 ng/mL
